The global blood group typing market is experiencing substantial growth due to the increasing demand for safe and accurate blood transfusion procedures across healthcare systems worldwide. The market size was valued at USD 2.31 billion in 2025 and is projected to reach USD 5.59 billion by 2033, growing at a CAGR of 11.99% from 2026 to 2033. Rising prevalence of chronic diseases such as anemia, cancer, and blood disorders continues to create strong demand for reliable blood typing technologies. Patients suffering from hematological disorders often require repeated blood transfusions, making precise blood compatibility testing essential for reducing transfusion-related complications and improving patient outcomes. The growing focus on personalized medicine, advanced diagnostics, and improved healthcare infrastructure is also contributing significantly to market expansion.

Another major factor accelerating market growth is the increasing number of surgical procedures, trauma cases, and organ transplant operations globally. Accurate blood group typing plays a critical role in ensuring transfusion safety during emergency care and complex surgeries. Technological advancements in molecular diagnostics and automation are transforming blood typing procedures by improving speed, efficiency, and accuracy. Healthcare institutions and diagnostic laboratories are increasingly adopting PCR-based and microarray-based technologies to minimize human errors and enhance testing precision. Furthermore, rising awareness regarding blood donation screening, expanding healthcare access in developing economies, and government initiatives supporting transfusion safety programs are expected to strengthen the market outlook over the forecast period.

Download a free sample copy of the Blood Group Typing market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         North America blood group typing market held the largest share of 44.85% of the global market in 2025. The region’s dominance is supported by advanced healthcare infrastructure, high adoption of molecular diagnostic technologies, strong presence of leading biotechnology companies, and increasing demand for blood transfusion procedures. In addition, growing investments in diagnostic research and rising incidence of chronic diseases are supporting regional market growth.

·         The blood group typing industry in Asia Pacific is expected to grow significantly over the forecast period. Rapid healthcare infrastructure development, increasing population, rising healthcare expenditure, and growing awareness regarding blood safety are key factors driving market growth across emerging economies in the region. Countries such as China, India, and Japan are witnessing increasing demand for advanced blood compatibility testing technologies due to expanding hospital networks and rising surgical volumes.

·         By product, the reagents & consumables segment held the highest market share of 71.49% in 2025. The segment continues to dominate due to frequent usage in blood typing procedures, recurring demand from diagnostic laboratories, and increasing testing volumes worldwide. Reagents and consumables are essential components in routine blood group testing, making them a critical revenue-generating segment within the industry.

·         By techniques, the PCR-based and microarray-based segment held the highest market share of 52.04% in 2025. These technologies are gaining significant traction due to their high sensitivity, accuracy, and ability to provide rapid diagnostic results. Molecular typing methods are increasingly preferred in complex transfusion cases and prenatal testing applications, further strengthening segment growth.

·         By test type, the antibody screening segment held the highest market share of 38.91% in 2025. Antibody screening is widely used to identify unexpected antibodies in donor and recipient blood samples, helping healthcare professionals reduce transfusion risks and improve compatibility assessment. The increasing emphasis on transfusion safety and precision diagnostics continues to drive demand for antibody screening solutions globally.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The blood group typing market is moderately fragmented, with the presence of both multinational corporations and regional players competing across product segments. Despite fragmentation, competition remains intense due to ongoing technological advancements and increasing demand for accurate transfusion diagnostics. Key companies operating in this market include Grifols S.A., Merck KGaA, Bio-Rad Laboratories, Inc., Immucor, Inc., Novacyt Group, Danaher Corporation, Agena Bioscience, Inc., Ortho Clinical Diagnostics, and Quotient, Ltd.. These companies are focusing on automation, product innovation, strategic partnerships, and global expansion strategies to strengthen their competitive position and meet the rising demand for advanced blood typing solutions.

Key Blood Group Typing Companies:

·        Grifols S.A.

·        Merck KGaA

·        Bio-Rad Laboratories, Inc.

·        Immucor, Inc

·        Novacyt Group

·        Danaher Corporation

·        Agena Bioscience, Inc.

·        Ortho Clinical Diagnostics

·        Quotient, Ltd.

Explore Grand View Horizon to see global and regional level statistics related to the Blood Group Typing Market

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering